Compare CRUS & ARWR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CRUS | ARWR |
|---|---|---|
| Founded | 1984 | 2003 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Semiconductors | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.1B | 8.0B |
| IPO Year | 1997 | 2009 |
| Metric | CRUS | ARWR |
|---|---|---|
| Price | $147.15 | $63.00 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 5 | 10 |
| Target Price | ★ $149.60 | $81.50 |
| AVG Volume (30 Days) | 466.9K | ★ 2.0M |
| Earning Date | 05-05-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 22.45 | ★ 99.80 |
| EPS | ★ 6.27 | 0.22 |
| Revenue | ★ $1,896,077,000.00 | $16,142,321.00 |
| Revenue This Year | $6.27 | N/A |
| Revenue Next Year | $1.84 | N/A |
| P/E Ratio | ★ $23.06 | $284.77 |
| Revenue Growth | ★ 5.99 | N/A |
| 52 Week Low | $75.83 | $10.66 |
| 52 Week High | $154.90 | $76.76 |
| Indicator | CRUS | ARWR |
|---|---|---|
| Relative Strength Index (RSI) | 59.63 | 57.29 |
| Support Level | $115.31 | $60.60 |
| Resistance Level | N/A | $66.37 |
| Average True Range (ATR) | 5.43 | 3.01 |
| MACD | 0.89 | 0.80 |
| Stochastic Oscillator | 68.36 | 81.55 |
Cirrus Logic Inc is a provider of integrated circuits for audio and voice signal processing applications. The firm's products are organized into two streams: portable audio products, and HPMS Products. These products include aAmplifiers, codecs, smart codecs, analog-to-digital converters, digital-to-analog converters and standalone digital signal processors, Camera controllers, haptics and sensing solutions, and battery and power ICs. Roughly half of the firm's revenue is generated in China, with the rest coming from the United States, Europe, South Korea, and countries across the world.
Arrowhead Pharmaceuticals Inc is an American biotechnology company. Its main target is the development of medicine to treat diseases with a genetic origin, characterized by the overproduction of one or more proteins. Its medical solutions are aimed at the genes that trigger the diseases. Its portfolio includes drugs targeting cardiovascular, Cardiometabolic, Central Nervous System, Pulmonary, Liver, Muscular, and Complement Mediated Disease. It majority products are liver disease curable.